Anavex updates Alzheimer's regulatory strategy, reports Q2 fiscal 2026 results

Anavex Life Sciences Corp. reported preliminary financial results for the fiscal quarter ended March 31, 2026 on July 30, 2026, alongside a business update on its clinical programs. The company's primary focus is on advancing its lead compound ANAVEX®2-73 (blarcamesine) for mild cognitive impairment and mild Alzheimer's disease, collectively called early AD, as well as for the neurodevelopmental rare diseases Rett syndrome and Fragile X syndrome.¹

On the Alzheimer's program, the company opened an Investigational New Drug application for early Alzheimer's disease with the FDA at the end of March 2026, a step it said enables U.S. clinical studies and supports substantive discussions with the FDA on future clinical development.¹ Two clinical pharmacology studies are proceeding under this IND, an ADME study and a drug-drug interaction study, with the ADME study expected to begin in the third quarter of calendar 2026 and dosing in the DDI study already underway.¹ Anavex intends to engage the FDA on a U.S. clinical development strategy for early Alzheimer's disease and said it continues to review the EMA's CHMP assessment report to help inform that strategy.¹

For Rett syndrome, the company has aligned with the FDA on a Phase 3 protocol for adults only and intends to discuss adding pediatric patients, with further program details expected later.¹ For Fragile X syndrome, the FDA has granted Orphan Drug Designation, and the company plans to begin discussions with the FDA on a clinical development strategy, with more details to come.¹

On Nasdaq listing status, Anavex submitted a plan on July 20, 2026 to regain compliance with Nasdaq Listing Rule 5250(c)(1).¹

On finances, preliminary cash and cash equivalents were $127.4 million as of March 31, 2026, compared to $102,577 thousand as of September 30, 2025.¹ The company said it expects this cash balance to fund operations into mid-to-late fiscal 2028.¹ The company cautioned that these results are preliminary and subject to completion of its financial closing procedures.¹